Intermediate density lipoprotein: Difference between revisions
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Intermediate density lipoprotein}} | ||
{{CMG}}; {{AE}} {{AN}}; {{RT}} | {{CMG}}; {{AE}} {{AN}}; {{RT}} | ||
== [[ | == [[Intermediate density lipoprotein overview|Overview]] == | ||
== [[ | == [[Intermediate density lipoprotein historical perspective|Historical Perspective]] == | ||
== [[ | == [[Intermediate density lipoprotein classification|Classification]] == | ||
== [[ | == [[Intermediate density lipoprotein biochemistry|Biochemistry]] == | ||
== [[ | == [[Intermediate density lipoprotein physiology|Physiology]] == | ||
== Clinical Correlation== | == Clinical Correlation== | ||
===[[High | ===[[High intermediate density lipoprotein]]=== | ||
[[High | [[High intermediate density lipoprotein epidemiology and demographics|Epidemiology and Demographics]] | [[High intermediate density lipoprotein pathophysiology|Pathophysiology]] | [[High intermediate density lipoprotein causes|Causes]] | [[High intermediate density lipoprotein diseases|Diseases]] | [[High intermediate density lipoprotein prognosis and complications|Prognosis and Complications]] | ||
===[[Low | ===[[Low Intermediate density lipoprotein]]=== | ||
[[Low | [[Low intermediate density lipoprotein epidemiology and demographics|Epidemiology and Demographics]] | [[Low intermediate density lipoprotein pathophysiology|Pathophysiology]] | [[Low intermediate density lipoprotein causes|Causes]] | [[Low intermediate density lipoprotein diseases|Diseases]] | [[Low intermediate density lipoprotein prognosis and complications|Prognosis and Complications]] | ||
== Treatment == | == Treatment == | ||
[[ | [[Intermediate density lipoprotein medical therapy|Medical Therapy]] | [[Intermediate density lipoprotein primary prevention|Primary Prevention]] | [[Intermediate density lipoprotein secondary prevention|Secondary Prevention]] | [[Intermediate density lipoprotein landmark trials|Landmark Trials]] | [[Intermediate density lipoprotein future or investigational therapies|Future or Investigational Therapies]] | ||
{{Lipoproteins}} | {{Lipoproteins}} |
Revision as of 17:09, 12 September 2013
Intermediate Density Lipoprotein Microchapters |
Clinical Correlation |
---|
Treatment |
Case Studies |
Intermediate density lipoprotein On the Web |
American Roentgen Ray Society Images of Intermediate density lipoprotein |
Directions to Hospitals Treating Intermediate density lipoprotein |
Risk calculators and risk factors for Intermediate density lipoprotein |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]
Overview
Historical Perspective
Classification
Biochemistry
Physiology
Clinical Correlation
High intermediate density lipoprotein
Epidemiology and Demographics | Pathophysiology | Causes | Diseases | Prognosis and Complications
Low Intermediate density lipoprotein
Epidemiology and Demographics | Pathophysiology | Causes | Diseases | Prognosis and Complications
Treatment
Medical Therapy | Primary Prevention | Secondary Prevention | Landmark Trials | Future or Investigational Therapies